Dataset Preview
Duplicate
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed
Error code:   DatasetGenerationError
Exception:    CastError
Message:      Couldn't cast
pool: struct<LQ000: list<item: string>, LQ001: list<item: string>, LQ002: list<item: string>, LQ003: list< (... 716 chars omitted)
  child 0, LQ000: list<item: string>
      child 0, item: string
  child 1, LQ001: list<item: string>
      child 0, item: string
  child 2, LQ002: list<item: string>
      child 0, item: string
  child 3, LQ003: list<item: string>
      child 0, item: string
  child 4, LQ004: list<item: string>
      child 0, item: string
  child 5, LQ005: list<item: string>
      child 0, item: string
  child 6, LQ006: list<item: string>
      child 0, item: string
  child 7, LQ007: list<item: string>
      child 0, item: string
  child 8, LQ008: list<item: string>
      child 0, item: string
  child 9, LQ009: list<item: string>
      child 0, item: string
  child 10, LQ010: list<item: string>
      child 0, item: string
  child 11, LQ011: list<item: string>
      child 0, item: string
  child 12, LQ012: list<item: string>
      child 0, item: string
  child 13, LQ013: list<item: string>
      child 0, item: string
  child 14, LQ014: list<item: string>
      child 0, item: string
  child 15, LQ015: list<item: string>
      child 0, item: string
  child 16, LQ016: list<item: string>
      child 0, item: string
  child 17, LQ017: list<item: string>
      child 0, item: string
  child 18, LQ018: list<item: string>
      child 0, item: string
  child 19, LQ019: list<item: string>
      child 0, item: string
  child 20, LQ020: list<item: string>
      child 0, item: string
  child 21, LQ021: list<item: string>
      child 0, item: string
  child 22, LQ022: list<item: string>
      child 0, item: string
  child 23, LQ023: list<item: string>
      child 0, item: string
  child 24, LQ024: list<item: string>
      child 0, item: string
  child 25, LQ025: list<item: string>
      child 0, item: string
  child 26, LQ026: list<item: string>
      child 0, item: string
  child 27, LQ027: list<item: string>
      child 0, item: string
  child 28, LQ028: list<item: string>
      child 0, item: string
  child 29, LQ029: list<item: string>
      child 0, item: string
config: struct<arms: list<item: string>, top_n: int64, pool_depth: int64, judge_model: string, seed: int64,  (... 33 chars omitted)
  child 0, arms: list<item: string>
      child 0, item: string
  child 1, top_n: int64
  child 2, pool_depth: int64
  child 3, judge_model: string
  child 4, seed: int64
  child 5, corpus: string
  child 6, embedder: string
to
{'text': Value('string'), 'pmid': Value('string'), 'pmcid': Value('string'), 'keyword': Value('string'), 'title': Value('string'), 'source': Value('string'), 'chunk_type': Value('string')}
because column names don't match
Traceback:    Traceback (most recent call last):
                File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1848, in _prepare_split_single
                  writer.write_table(table)
                  ~~~~~~~~~~~~~~~~~~^^^^^^^
                File "/usr/local/lib/python3.14/site-packages/datasets/arrow_writer.py", line 764, in write_table
                  self.write_rows_on_file()  # in case there are buffered rows to write first
                  ~~~~~~~~~~~~~~~~~~~~~~~^^
                File "/usr/local/lib/python3.14/site-packages/datasets/arrow_writer.py", line 663, in write_rows_on_file
                  self._write_table(table)
                  ~~~~~~~~~~~~~~~~~^^^^^^^
                File "/usr/local/lib/python3.14/site-packages/datasets/arrow_writer.py", line 773, in _write_table
                  pa_table = table_cast(pa_table, self._schema)
                File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2378, in table_cast
                  return cast_table_to_schema(table, schema)
                File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2306, in cast_table_to_schema
                  raise CastError(
                  ...<3 lines>...
                  )
              datasets.table.CastError: Couldn't cast
              pool: struct<LQ000: list<item: string>, LQ001: list<item: string>, LQ002: list<item: string>, LQ003: list< (... 716 chars omitted)
                child 0, LQ000: list<item: string>
                    child 0, item: string
                child 1, LQ001: list<item: string>
                    child 0, item: string
                child 2, LQ002: list<item: string>
                    child 0, item: string
                child 3, LQ003: list<item: string>
                    child 0, item: string
                child 4, LQ004: list<item: string>
                    child 0, item: string
                child 5, LQ005: list<item: string>
                    child 0, item: string
                child 6, LQ006: list<item: string>
                    child 0, item: string
                child 7, LQ007: list<item: string>
                    child 0, item: string
                child 8, LQ008: list<item: string>
                    child 0, item: string
                child 9, LQ009: list<item: string>
                    child 0, item: string
                child 10, LQ010: list<item: string>
                    child 0, item: string
                child 11, LQ011: list<item: string>
                    child 0, item: string
                child 12, LQ012: list<item: string>
                    child 0, item: string
                child 13, LQ013: list<item: string>
                    child 0, item: string
                child 14, LQ014: list<item: string>
                    child 0, item: string
                child 15, LQ015: list<item: string>
                    child 0, item: string
                child 16, LQ016: list<item: string>
                    child 0, item: string
                child 17, LQ017: list<item: string>
                    child 0, item: string
                child 18, LQ018: list<item: string>
                    child 0, item: string
                child 19, LQ019: list<item: string>
                    child 0, item: string
                child 20, LQ020: list<item: string>
                    child 0, item: string
                child 21, LQ021: list<item: string>
                    child 0, item: string
                child 22, LQ022: list<item: string>
                    child 0, item: string
                child 23, LQ023: list<item: string>
                    child 0, item: string
                child 24, LQ024: list<item: string>
                    child 0, item: string
                child 25, LQ025: list<item: string>
                    child 0, item: string
                child 26, LQ026: list<item: string>
                    child 0, item: string
                child 27, LQ027: list<item: string>
                    child 0, item: string
                child 28, LQ028: list<item: string>
                    child 0, item: string
                child 29, LQ029: list<item: string>
                    child 0, item: string
              config: struct<arms: list<item: string>, top_n: int64, pool_depth: int64, judge_model: string, seed: int64,  (... 33 chars omitted)
                child 0, arms: list<item: string>
                    child 0, item: string
                child 1, top_n: int64
                child 2, pool_depth: int64
                child 3, judge_model: string
                child 4, seed: int64
                child 5, corpus: string
                child 6, embedder: string
              to
              {'text': Value('string'), 'pmid': Value('string'), 'pmcid': Value('string'), 'keyword': Value('string'), 'title': Value('string'), 'source': Value('string'), 'chunk_type': Value('string')}
              because column names don't match
              
              During handling of the above exception, another exception occurred:
              
              Traceback (most recent call last):
                File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1850, in _prepare_split_single
                  raise DatasetGenerationCastError.from_cast_error(
                  ...<4 lines>...
                  )
              datasets.exceptions.DatasetGenerationCastError: An error occurred while generating the dataset
              
              All the data files must have the same columns, but at some point there are 2 new columns ({'pool', 'config'}) and 7 missing columns ({'title', 'keyword', 'text', 'pmid', 'pmcid', 'source', 'chunk_type'}).
              
              This happened while the json dataset builder was generating data using
              
              hf://datasets/mohamedkhaledmk7/LUMEN-rag-data/qrels/lumen_queries.jsonl (at revision 0b5e82fd55cf64cb6401a1600e7d4fd592fb1528), ['hf://datasets/mohamedkhaledmk7/LUMEN-rag-data@0b5e82fd55cf64cb6401a1600e7d4fd592fb1528/SpubMedBERT_chunks.json', 'hf://datasets/mohamedkhaledmk7/LUMEN-rag-data@0b5e82fd55cf64cb6401a1600e7d4fd592fb1528/qrels/lumen_pool.json', 'hf://datasets/mohamedkhaledmk7/LUMEN-rag-data@0b5e82fd55cf64cb6401a1600e7d4fd592fb1528/qrels/lumen_queries.jsonl'], ['hf://datasets/mohamedkhaledmk7/LUMEN-rag-data@0b5e82fd55cf64cb6401a1600e7d4fd592fb1528/SpubMedBERT_chunks.json', 'hf://datasets/mohamedkhaledmk7/LUMEN-rag-data@0b5e82fd55cf64cb6401a1600e7d4fd592fb1528/qrels/lumen_pool.json', 'hf://datasets/mohamedkhaledmk7/LUMEN-rag-data@0b5e82fd55cf64cb6401a1600e7d4fd592fb1528/qrels/lumen_queries.jsonl']
              
              Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)
              
              During handling of the above exception, another exception occurred:
              
              Traceback (most recent call last):
                File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1869, in _prepare_split_single
                  num_examples, num_bytes = writer.finalize()
                                            ~~~~~~~~~~~~~~~^^
                File "/usr/local/lib/python3.14/site-packages/datasets/arrow_writer.py", line 781, in finalize
                  self.write_rows_on_file()
                  ~~~~~~~~~~~~~~~~~~~~~~~^^
                File "/usr/local/lib/python3.14/site-packages/datasets/arrow_writer.py", line 663, in write_rows_on_file
                  self._write_table(table)
                  ~~~~~~~~~~~~~~~~~^^^^^^^
                File "/usr/local/lib/python3.14/site-packages/datasets/arrow_writer.py", line 773, in _write_table
                  pa_table = table_cast(pa_table, self._schema)
                File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2378, in table_cast
                  return cast_table_to_schema(table, schema)
                File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2306, in cast_table_to_schema
                  raise CastError(
                  ...<3 lines>...
                  )
              datasets.table.CastError: Couldn't cast
              pool: struct<LQ000: list<item: string>, LQ001: list<item: string>, LQ002: list<item: string>, LQ003: list< (... 716 chars omitted)
                child 0, LQ000: list<item: string>
                    child 0, item: string
                child 1, LQ001: list<item: string>
                    child 0, item: string
                child 2, LQ002: list<item: string>
                    child 0, item: string
                child 3, LQ003: list<item: string>
                    child 0, item: string
                child 4, LQ004: list<item: string>
                    child 0, item: string
                child 5, LQ005: list<item: string>
                    child 0, item: string
                child 6, LQ006: list<item: string>
                    child 0, item: string
                child 7, LQ007: list<item: string>
                    child 0, item: string
                child 8, LQ008: list<item: string>
                    child 0, item: string
                child 9, LQ009: list<item: string>
                    child 0, item: string
                child 10, LQ010: list<item: string>
                    child 0, item: string
                child 11, LQ011: list<item: string>
                    child 0, item: string
                child 12, LQ012: list<item: string>
                    child 0, item: string
                child 13, LQ013: list<item: string>
                    child 0, item: string
                child 14, LQ014: list<item: string>
                    child 0, item: string
                child 15, LQ015: list<item: string>
                    child 0, item: string
                child 16, LQ016: list<item: string>
                    child 0, item: string
                child 17, LQ017: list<item: string>
                    child 0, item: string
                child 18, LQ018: list<item: string>
                    child 0, item: string
                child 19, LQ019: list<item: string>
                    child 0, item: string
                child 20, LQ020: list<item: string>
                    child 0, item: string
                child 21, LQ021: list<item: string>
                    child 0, item: string
                child 22, LQ022: list<item: string>
                    child 0, item: string
                child 23, LQ023: list<item: string>
                    child 0, item: string
                child 24, LQ024: list<item: string>
                    child 0, item: string
                child 25, LQ025: list<item: string>
                    child 0, item: string
                child 26, LQ026: list<item: string>
                    child 0, item: string
                child 27, LQ027: list<item: string>
                    child 0, item: string
                child 28, LQ028: list<item: string>
                    child 0, item: string
                child 29, LQ029: list<item: string>
                    child 0, item: string
              config: struct<arms: list<item: string>, top_n: int64, pool_depth: int64, judge_model: string, seed: int64,  (... 33 chars omitted)
                child 0, arms: list<item: string>
                    child 0, item: string
                child 1, top_n: int64
                child 2, pool_depth: int64
                child 3, judge_model: string
                child 4, seed: int64
                child 5, corpus: string
                child 6, embedder: string
              to
              {'text': Value('string'), 'pmid': Value('string'), 'pmcid': Value('string'), 'keyword': Value('string'), 'title': Value('string'), 'source': Value('string'), 'chunk_type': Value('string')}
              because column names don't match
              
              The above exception was the direct cause of the following exception:
              
              Traceback (most recent call last):
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1369, in compute_config_parquet_and_info_response
                  parquet_operations, partial, estimated_dataset_info = stream_convert_to_parquet(
                                                                        ~~~~~~~~~~~~~~~~~~~~~~~~~^
                      builder, max_dataset_size_bytes=max_dataset_size_bytes
                      ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
                  )
                  ^
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 948, in stream_convert_to_parquet
                  builder._prepare_split(split_generator=splits_generators[split], file_format="parquet")
                  ~~~~~~~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1694, in _prepare_split
                  for job_id, done, content in self._prepare_split_single(
                                               ~~~~~~~~~~~~~~~~~~~~~~~~~~^
                      gen_kwargs=gen_kwargs, job_id=job_id, **_prepare_split_args
                      ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
                  ):
                  ^
                File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1880, in _prepare_split_single
                  raise DatasetGenerationError("An error occurred while generating the dataset") from e
              datasets.exceptions.DatasetGenerationError: An error occurred while generating the dataset

Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.

text
string
pmid
string
pmcid
string
keyword
string
title
string
source
string
chunk_type
string
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series Background Immune checkpoint inhibitors (ICIs) are the gold standard therapy for cutaneous melanoma and are also used effectively in treating other types of skin cancer. Hematologic toxicities are...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Clinical and biological biomarkers able to predict these events have been poorly explored and have not yet been identified. Case presentation We present four cases of hematologic toxicity in melanoma patients and one case in a patient with cutaneous squamous cell carcinoma, all of which arose during treatment with ICIs...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
Hemolytic anemia was the most frequent event; neutropenia with agranulocytosis happened in one case and was fatal. ICI treatment was discontinued in all five cases and was never restarted. Two prevalent features were male sex and older age (>70 years old).
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
Two prevalent features were male sex and older age (>70 years old). These events were independent of the response to ICIs. Indeed, they occurred in a patient who progressed during treatment and in patients who responded completely to therapy.
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Indeed, they occurred in a patient who progressed during treatment and in patients who responded completely to therapy. Previous diarrhea due to ICIs (patients 1, 2, and 5), asthenia (patients 3 and 4), and a sudden increase in lactate dehydrogenase levels despite the absence of disease progression (patients 2, 3, 4, a...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
Conclusion Our study underscores the rarity and potential severity of hematologic toxicities, underlining the need for heightened clinician awareness and the incorporation of hematologic guidance into oncologic practice. Although predictive biomarkers remain unvalidated, monitoring immune cell subsets or recognizing wa...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
1 Introduction Immune checkpoint inhibitors (ICIs) have transformed the treatment of patients with early- and late-stage melanoma by improving clinical and radiological responses and extending overall survival ( Carlino et al., 2021 ). Despite their efficacy, ICIs can induce immune-related adverse events (irAEs), which...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Hematologic toxicities are rare irAEs induced by ICIs, either as monotherapy or in combination. Currently, descriptions of these events are limited to case reports or retrospective analyses ( Davis et al., 2019 ; Delanoy et al., 2019 ; Kroll et al., 2022 ). Due to the rarity of hematologic toxicities and the difficulty...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Due to the rarity of hematologic toxicities and the difficulty of diagnosing them, it is challenging to estimate their incidence. However, some authors suggest frequencies of 3.6% for all grades of toxicity and 0.7% for grades 3–4 ( Michot et al., 2019 ). Toxicities of all grades were found to be higher with anti–progr...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Toxicities of all grades were found to be higher with anti–programmed cell death-1 (PD-1) (4.1%) (nivolumab or pembrolizumab) or anti–programmed cell death-ligand 1 (PD-L1) (4.7%) than with anti–cytotoxic T-lymphocyte–associated protein 4 (CTLA4) (0.5%) (ipilimumab) ( Michot et al., 2019 ). The mortality rate for high-...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Due to their rarity and the poor understanding of their clinical presentation and spectrum of events, they are not always recognized and promptly managed. The range of clinical manifestations includes immune thrombocytopenia, aplastic anemia, pancytopenia, neutropenia, autoimmune hemolytic anemia (AIHA), bicytopenia, p...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
The time to onset varies; half of hematologic irAEs appear within the first 10 weeks after ICIs are initiated, with most resolving within one to 2 months ( Delanoy et al., 2019 ). Regarding the anti-PD-1 antibody cemiplimab, which is used to treat skin squamous cell carcinoma, a study reported only neutropenia occurren...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Although rare, the widespread use of ICIs to treat various cancer types increases the likelihood of encountering hematologic irAEs ( Keam et al., 2024 ). Therapeutic strategies include the use of steroids, intravenous immunoglobulins, rituximab, blood component transfusions, growth factor support, and immunosuppressant...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
Early consultation with a hematologist is advised for diagnosis and management. A bone marrow examination should be considered to rule out other causes of pancytopenia, such as marrow infiltration, secondary myelodysplastic syndrome, or aplastic anemia. Currently, there are no identified predisposing risk factors or pr...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
Currently, there are no identified predisposing risk factors or prognostic biomarkers that can prevent patients from developing such toxicities. 2 Case series We present five cases of skin cancer patients ( Table 1 ) we observed in a period of 3 years who developed grade 2 to 4 hematologic toxicity to ICI therapy, as g...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Four patients had cutaneous or mucosal melanomas, and one patient had cutaneous squamous cell carcinoma. Data regarding comorbidities, medications, relapse, follow-up, and rechallenge with ICIs are presented in Table 2 . Data on available hematologic elements are reported in Table 3 .
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Data on available hematologic elements are reported in Table 3 . TABLE 1 Clinical characteristics of the patients. Patient/sex Age (years) Tumor mutation -PD-L1 expression ICI Setting Hematologic event – grading a Time to event (mo) Best response to ICI Death 1M 73 BRAF wt c-KIT wt N-RAS n.a.
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Patient/sex Age (years) Tumor mutation -PD-L1 expression ICI Setting Hematologic event – grading a Time to event (mo) Best response to ICI Death 1M 73 BRAF wt c-KIT wt N-RAS n.a. PD-L1 < 1 Nivolumab + ipilimumab 1 st L Agranulocytosis G4 3.5 PD Y 2M 74 BRAF wt N-RAS Q61X PD-L1 < 1 Ipilimumab 2 nd L AIHA G4 0.5 PR N 3M ...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Nivolumab adj AIHA G4 7 NED N 4F 78 BRAF K601E PD-L1 > 1 Pembrolizumab adj AIHA G2 1.5 NED N 5M 78 n.a. Cemiplimab 1 st L MDS G4 4 CR Y M: male, F: female, ICI: checkpoint inhibitor immunotherapy, L: line of treatment, G: grading, AIHA: autoimmune hemolytic anemia, MDS: myelodysplastic syndrome, adj: adjuvant, NED: no ...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
: not available, BRAF: B-Raf proto-oncogene, N-RAS: Neuroblastoma RAS, Viral (V-Ras), wt: wild type, PD-L1: programmed cell death-ligand 1. a Toxicities were graded according to CTCAE v5.0 criteria. TABLE 2 Clinical data on patient clinical situations and outcomes. Patient Comorbidies Concomitant drugs Response to irAE...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Patient Comorbidies Concomitant drugs Response to irAE treatments Last f-up Relapse - progression Current status a Rechallenge 1 None None No 11/2024 (death) Yes - No 2 -Arterial hypertension -Benign prostatic hyperplasia Valsartan Dutasteride Yes 11/2025 Yes Palliative No 3 -Arterial hypertension -Benign prostatic hyp...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
TABLE 3 Transfusion details and outcome. Patient Transfusion number of unit Reactions to transfusion Threshold Steroid treatment a 1 None NA 8 Concomitant 2 7 None 7 After 3 3 None 7 Concomitant 4 None NA 8 After 5 None NA 8 Concomitant NA: not applicable. Concomitant: the patient was under steroid treatment at the tim...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
Concomitant: the patient was under steroid treatment at the time of the irAE. After: the patient received steroid treatment after the diagnosis of the irAE. 2.1 Case 1 2.1.1 Patient information and clinical findings The first case was a 73-year-old man with metastatic mucosal melanoma of the anorectal junction, which w...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
2.1 Case 1 2.1.1 Patient information and clinical findings The first case was a 73-year-old man with metastatic mucosal melanoma of the anorectal junction, which was diagnosed in July 2024. The patient was in good clinical condition and had no comorbidities in his medical history. The melanoma was BRAF wild-type and ne...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
The melanoma was BRAF wild-type and negative for c-KIT and PD-L1. Due to the extent of the disease, which included multiple bilateral iliac, obturator, and presacral lymph nodes, as well as symptoms, the patient began palliative radiotherapy on the primary tumor and systemic immunotherapy with ipilimumab (3 mg/kg), plu...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
2.1.2 Timeline After the first cycle of immunotherapy, the patient developed grade 3 diarrhea, which went into remission after receiving a 1 mg/kg dose of steroids. Due to toxicity and limited treatment options, ipilimumab was discontinued and nivolumab was administered for two additional cycles without the appearance ...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
However, a computed tomography (CT) scan performed in October 2024 revealed significant disease progression in the liver, lungs, and lymph nodes. Lactate dehydrogenase (LDH) increased to 486 U/L. The patient was admitted to the hospital for a liver biopsy.
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
The patient was admitted to the hospital for a liver biopsy. On the first day, the patient had grade 4 febrile neutropenia: 2.0 × 10 3 μL white blood cells, 0.01 × 10 3 μL neutrophils, 1.75 × 10 3 μL lymphocytes, and 0.05 × 10 3 μL monocytes. His hemoglobin and platelet levels were within normal values, and his C-react...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
His hemoglobin and platelet levels were within normal values, and his C-reactive protein (CRP) level was 162.9 mg/L. 2.1.3 Outcomes and follow-up Over the next month, the patient received meropenem, piperacillin/tazobactam, high-dose intravenous steroids, an antimycotic, and daily granulocyte colony-stimulating factor,...
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
general
A bone marrow biopsy showed aplasia limited to the myeloid cells. The patient became depressed and decided to go home against medical advice. The patient died the day after, just 4 months after the melanoma diagnosis.
41567626
PMC12816168
melanoma signs symptoms warning
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.
full_text
symptom
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010–2023) Background Paraneoplastic ocular syndromes are rare, immune-mediated disorders triggered by malignancies. They may precede cancer diagnosis or signal its recurrence, highlighting their potential value as early warn...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
Their recognition is critical for timely diagnosis and appropriate management. Methods We performed a systematic review of case reports and case series published between 2010 and 2023 in PubMed database, focusing on six major syndromes: cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), bilater...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
We extracted demographic, clinical, immunologic, oncologic, therapeutic, and outcome-related data. Results A total of 132 articles comprising 147 patients were included: 53 with CAR, 22 with MAR, 26 with BDUMP, 16 with AEPPVM, 11 with PU, and 19 with PON. Visual impairment was bilateral in over 90% of cases.
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Visual impairment was bilateral in over 90% of cases. The most frequently associated malignancies were lung cancers (notably small-cell lung carcinoma), gynecological cancers, and melanoma. Onconeural autoantibodies were tested in serum—most commonly revealing anti-recoverin and anti-alpha-enolase in CAR, and anti-CRMP...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Onconeural autoantibodies were tested in serum—most commonly revealing anti-recoverin and anti-alpha-enolase in CAR, and anti-CRMP5 in PON—but were never assessed in cerebrospinal fluid (CSF), despite its potential diagnostic value. Therapeutic approach was highly heterogeneous and largely empirical, with systemic cort...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Visual prognosis varied but was especially poor in CAR, for which 49.1% of patients experienced worsening vision. Notably, in CAR, an early oncologic diagnosis (within 6 months after symptom onset) was significantly associated with a favorable visual outcome ( p = 0.03). Conclusion We identified a clinical profile of p...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
Conclusion We identified a clinical profile of patients in whom paraneoplastic ocular syndromes should be suspected. These rare inflammatory disorders may serve as early indicators of malignancy. Further studies are needed to improve diagnostic pathways, optimize immunologic workup (including CSF testing), and guide th...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Further studies are needed to improve diagnostic pathways, optimize immunologic workup (including CSF testing), and guide therapeutic strategies. Supplementary Information The online version contains supplementary material available at 10.1186/s12348-025-00534-1. Introduction Paraneoplastic syndromes are systemic manif...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
Introduction Paraneoplastic syndromes are systemic manifestations associated with malignancies that are not directly attributable to local or metastatic tumor invasion, and that cannot be explained by nutritional deficiencies, metabolic disorders, infections or iatrogenic causes [ 1 ]. Paraneoplastic syndromes affect a...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
Bronchopulmonary cancers – especially small-cell lung carcinomas – are the most commonly associated malignancies. Although rare, these manifestations can be used as early markers of malignancy, and thus represent a major diagnostic challenge. The term “masquerade syndrome” was first introduced in 1967 to describe a cas...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
The term “masquerade syndrome” was first introduced in 1967 to describe a case of conjunctival carcinoma initially misdiagnosed as chronic and resistant conjunctivitis [ 3 ]. The concept was subsequently extended to a range of ocular pathologies which, by mimicking chronic idiopathic inflammation, can delay the identif...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
In fact, these inflammatory manifestations correspond either to ocular neoplastic disorders (e.g. intraocular lymphoma or retinoblastoma), or to ocular paraneoplastic disorders [ 4 ]. This work focuses on the latter etiology.
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
This work focuses on the latter etiology. Ocular paraneoplastic disorders were first described in 1976. They remain a rare entity, affecting only 0.01% of patients with malignancies [ 5 ].
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
They remain a rare entity, affecting only 0.01% of patients with malignancies [ 5 ]. Their rarity, associated with their polymorphic clinical presentation, makes their recognition and diagnosis particularly challenging. The eye is theoretically protected from pathogenic inflammatory reactions to prevent significant los...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
The eye is theoretically protected from pathogenic inflammatory reactions to prevent significant loss of function due to tissue damage. In this respect, several mechanisms contribute to its immunological privilege, providing a state of immune tolerance. These include secretion of intraocular immunosuppressive factors, ...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
These include secretion of intraocular immunosuppressive factors, major histocompatibility complex class II low expression, and effector T cells conversion into regulatory T cells, Programmed Death-Ligand 1 and Fas-Ligand expression, which induce apoptosis of immune cells [ 6 ]. One explanation for the occurrence of oc...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
In this context, the host immune response, initially directed against the tumor, triggers the production of autoantibodies capable of recognizing these antigens in remote tissues, leading to potentially severe ophthalmic damage. One example is recoverin, a photoreceptor-specific protein involved in cancer-associated re...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Ocular paraneoplastic disorders can take different clinical forms. They represent an important warning signal and can sometimes precede the discovery of cancer, occur in parallel with its progression, or herald a recurrence. This study aimed to provide a comprehensive description of these ophthalmic inflammatory phenom...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
This study aimed to provide a comprehensive description of these ophthalmic inflammatory phenomena associated with cancer through a systematic review of the literature between 2010 and 2023. Methods The PubMed database was used to conduct a systematic literature review, using the keywords: “cancer-associated retinopath...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
A single reviewer screened all abstracts retrieved to finalize article selection. The set of identified articles was cross-referenced with those retrieved from a search using the MESH term “paraneoplastic ocular syndromes “. Inclusion criteria were: clinical case descriptions and clinical case series, published between...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Inclusion criteria were: clinical case descriptions and clinical case series, published between January 2010 and December 2023, with an available abstract, in French and English. Exclusion criteria were: general reviews, pathophysiology articles, exclusive therapeutic reviews, and pediatric cases. Collected information...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
Collected information included age, sex, age at diagnosis of the ophthalmic condition, age at oncological diagnosis, type of ophthalmic condition and associatedclinical and paraclinical data at diagnosis (visual acuity at diagnosis, slit-lamp examination, fundus examination, angiography, optical coherence tomography (O...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
The secondary aims were to describe clinical data related to ophthalmic conditions, biological data focusing on autoantibodies, investigate the timeline between ophthalmic conditions and cancer diagnosis, describe immunosuppressive treatments used for ophthalmic conditions, and assess the evolution of ophthalmic condit...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
Percentages and frequencies of demographic, clinical, and biological variables were calculated for the entire study population as well as for the subgroup of patients with available clinical outcome data. When visual progression data were available, qualitative data comparisons between subgroups of patients with favora...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Quantitative data comparisons between the two groups were conducted using the Student’s t-test or the Wilcoxon-Mann-Whitney exact test when the sample size was below five per group. Results Enrolled population A literature search of the PubMed database identified 481 articles related to ocular paraneoplastic syndromes ...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Among these 481 articles, 155 focused on cancer associated retinopathy (CAR, 32.2%), 83 on melanoma associated retinopathy (MAR, 17.3%), 48 on acute exudative polymorphous paraneoplastic vitelliform maculopathy (AEPPVM, 10%), 94 on bilateral diffuse uveal melanocytic proliferation (BDUMP, 19.5%), 64 on paraneoplastic u...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Ultimately, from January 1, 2010, to December 31, 2023, 132 case reports or case series were included in this systematic literature review, comprising: 48 articles on CAR, 22 on MAR, 14 on AEPPVM, 21 on BDUMP, 11 on paraneoplastic uveitis, and 16 on paraneoplastic optic neuropathies (Fig. 1 Flow chart of reports select...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
CAR: Carcinoma associated retinopathy, MAR: Melanoma associated retinopathy, AEPPVM: Acute exudative paraneoplastic polymorphous vitelliform maculopathy, BDUMP: Bilateral diffuse uveal melanocytic proliferation, PU: paraneoplastic uveitis, PON: paraneoplastic optic neuropathy. Details of the studies included in this re...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Demographic data There was no significant difference in mean age between the groups of patients according to each ophthalmic condition ( p = 0.2) (Table 1 ). Mean ages were 61.9 years for CAR, 67.1 years for MAR, 66.5 years for BDUMP, 58.3 years for AEPPVM, 54.8 years for paraneoplastic uveitis, and 63.6 years for para...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
general
Although no significant difference in sex was observed between the groups ( p = 0.2), a trend was noted in some subgroups. In the MAR, BDUMP, and AEPPVM groups, males predominated, with male-to-female ratios of 2.1 (68.2% vs. 31.8%), 1.8 (65.4% vs. 34.6%), and 2.2 (68.7% vs. 31.3%), respectively. Table 1 General and op...
41003888
PMC12474834
melanoma signs symptoms warning
Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010-2023).
full_text
symptom
FDA Approval Summary: Afamitresgene Autoleucel for Adults With HLA-Restricted MAGE-A4 Positive Unresectable or Metastatic Synovial Sarcoma After Prior Chemotherapy On August 1, 2024, the FDA granted accelerated approval to afamitresgene autoleucel, a melanoma-associated antigen-A4 (MAGE-A4)-directed genetically modifi...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Patients received a single dose of afamitresgene autoleucel following lymphodepleting chemotherapy. Of the 44 efficacy evaluable patients, the overall response rate was 43.2% (95% CI: 28.4, 59.0), with complete response in two patients (4.5%). The median duration of response was 6.0 months (95% CI: 4.6, not reached [NR...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
The median duration of response was 6.0 months (95% CI: 4.6, not reached [NR]) with a median follow-up of 21.9 months. Among the 44 patients, cytokine release syndrome occurred in 75% (Grade ≥3, 2%) warranting a Boxed Warning. Grade ≥3 infections occurred in 14% of patients and prolonged severe cytopenias also occurred...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
symptom
Grade ≥3 infections occurred in 14% of patients and prolonged severe cytopenias also occurred. One patient developed Grade 1 immune effector cell-associated neurotoxicity and one patient developed Epstein-Barr virus-positive lymphoproliferative disease. Notably, during review of this application, FDA identified issues ...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
symptom
Notably, during review of this application, FDA identified issues with data quality and study conduct that prompted an independent re-review of imaging assessments. The results of the re-review were the basis for FDA’s determination of substantial evidence of effectiveness. This represents the first FDA approval of a T...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
This represents the first FDA approval of a T-cell receptor gene therapy. It is also the first FDA approval specifically for SS, representing a new treatment modality for this rare population who lack effective therapies. Introduction On August 1, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Introduction On August 1, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (Tecelra) for the treatment of adults with unresectable or metastatic synovial sarcoma (SS) who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumors express the m...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Synovial sarcoma is a rare soft-tissue sarcoma (STS) affecting 800 to 1,000 people in the U.S. annually. It primarily occurs in adolescents and young adults. Approximately 50% of patients with SS develop recurrent or metastatic disease following standard-of-care treatment ( 3 ).
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Approximately 50% of patients with SS develop recurrent or metastatic disease following standard-of-care treatment ( 3 ). Advanced unresectable and metastatic SS has a poor prognosis, with a reported median overall survival (OS) of approximately 16 to 24 months ( 3 , 4 ). While standard first-line treatment of advanced...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
While standard first-line treatment of advanced unresectable or metastatic SS includes combination anthracycline-based chemotherapy regimens, there is no consensus on optimal second-line therapy. The kinase inhibitor pazopanib is approved in the U.S. for patients with STS who received prior chemotherapy ( 5 ). Before t...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Before this approval, there were no U.S. Food and Drug Administration (FDA)-approved therapies specifically for SS in any treatment setting. Afamitresgene autoleucel is a genetically modified autologous T-cell immunotherapy consisting of cluster of differentiation (CD)4- and CD8-positive T cells transduced with a self-...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
The transduced, autologous T cells express an enhanced-affinity T-cell receptor (TCR) specific for HLA-A*02-restricted MAGE-A4 peptides. MAGE-A4 is a cancer-testis antigen with restricted expression in normal tissues that is overexpressed in the majority of SS ( 6 ). This report summarizes the FDA’s clinical review and...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
This report summarizes the FDA’s clinical review and regulatory decision making. Trial Design The safety and efficacy of afamitresgene autoleucel was evaluated in Study ADP-0044–002 (Spearhead 1; NCT04044768 ), a phase 2, single-arm, open-label, multicenter, multicohort clinical trial of afamitresgene autoleucel. Eligi...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Eligible patients were required to be 16 years of age or older with MAGE-A4 expressing advanced SS or myxoid/round cell liposarcoma who had received at least one prior line of chemotherapy. Patients were required to have an ECOG performance status of ≤1, have been treated with prior anthracycline- or ifosfamide-contain...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
MAGE-A4 expression was defined as a 2+ staining in ≥30% of the cells by an immunohistochemistry (IHC) clinical trial assay at a centralized testing site. The study excluded patients who were positive for HLA-A*02:05 allele, had symptomatic central nervous system (CNS) metastases, or had received or planned to receive a...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Following lymphodepleting chemotherapy with fludarabine 30 mg/m 2 /day for 4 days (Days −7 to −4) and cyclophosphamide 600 mg/m 2 /day for 3 days (Days −7 to −5), patients received a single infusion of afamitresgene autoleucel at the recommended dose range of 2.68 × 10 9 to 10 × 10 9 MAGE-A4 TCR-positive T cells on Day...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Patients remained hospitalized for observation for at least 24 hours post-T-cell infusion. The primary efficacy endpoint was overall response rate (ORR) as assessed by an independent review committee (IRC) according to RECIST v.1.1. Duration of response (DOR) was a key secondary endpoint.
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Duration of response (DOR) was a key secondary endpoint. The primary evidence to support the safety and effectiveness derives from Cohort 1 of Study ADP-0044–002; Cohort 2 provided supportive safety data. Trial Results Study Population Of the 52 patients with SS enrolled in Cohort 1, 45 patients (87%) received lymphode...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Trial Results Study Population Of the 52 patients with SS enrolled in Cohort 1, 45 patients (87%) received lymphodepletion and 44 (85%) received afamitresgene autoleucel. The primary efficacy analysis population consists of patients with SS treated with afamitresgene autoleucel in Cohort 1 (i.e., the modified intent-to...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
The median time from leukapheresis to start of lymphodepletion for the primary efficacy analysis population was 1.7 months. The demographic and baseline characteristics of the mITT population are shown in Table 1 . Sixty-four percent (28 of 44) of patients lived in the United States and 82% of patients were between the...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Sixty-four percent (28 of 44) of patients lived in the United States and 82% of patients were between the ages of 18 and 49. The study enrolled no pediatric patients. Sixteen patients (36.4%) received bridging therapy, with pazopanib (25%), ifosfamide (7%), trabectedin (2%), or doxorubicin (2%).
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Sixteen patients (36.4%) received bridging therapy, with pazopanib (25%), ifosfamide (7%), trabectedin (2%), or doxorubicin (2%). The median dose of afamitresgene autoleucel administered was 8 × 10 9 MAGE-A4 TCR-positive T cells (range: 2.68 × 10 9 to 9.99 × 10 9 ). Efficacy The efficacy results are shown in Table 2 .
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Efficacy The efficacy results are shown in Table 2 . The ORR was 43.2% (95% CI: 28.4, 59.0). The median duration of follow-up for all patients was 21.9 months by reverse Kaplan Meier (KM) estimate.
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
The median duration of follow-up for all patients was 21.9 months by reverse Kaplan Meier (KM) estimate. Among the 19 patients who achieved a response, durable response at 6, 12, and 24 months was 45.6%, 39.0%, and 39.0%, respectively, based on KM estimate. DOR was censored for 8 of the 19 responders (42%) as of the da...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
DOR was censored for 8 of the 19 responders (42%) as of the data cut-off. Reasons for censoring included being alive and progressive disease free (n=5), end of intervention phase before progressive disease (n=2), and missing imaging assessments (n=1). Safety The primary safety analysis population consists of the 44 pat...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Safety The primary safety analysis population consists of the 44 patients with SS enrolled in Cohort 1 who received afamitresgene autoleucel within the intended dose range. The most common adverse reactions are shown in Table 3 . Grade 3 or 4 laboratory abnormalities that worsened from baseline and occurred in ≥20% of ...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
symptom
Grade 3 or 4 laboratory abnormalities that worsened from baseline and occurred in ≥20% of patients were lymphopenia, neutropenia, leukopenia, anemia, and thrombocytopenia. A total of 37 patients died during the study, 24 patients in Cohort 1. All deaths were due to disease under study and occurred >30 days after afamit...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
symptom
All deaths were due to disease under study and occurred >30 days after afamitresgene autoleucel administration except for one patient in Cohort 2 who died due to septic shock 9 days after afamitresgene autoleucel administration and after the data cut-off date. All but one case of CRS were Grade 1 or 2 in severity and t...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
general
Only one case of immune effector cell-associated neurotoxicity syndrome (ICANS) (Grade 1) occurred, with a time to onset of 2 days and time to resolution of 1 day. Grade ≥3 cytopenia not resolved by Week 4 was considered prolonged. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia not resolved by Week 4 occurred i...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
symptom
Grade 3 or 4 anemia, neutropenia, and thrombocytopenia not resolved by Week 4 occurred in 9%, 11%, and 5% of patients, respectively. The median time to resolution was 7.3 weeks for anemia, 9.3 weeks for neutropenia, and 6.3 weeks for thrombocytopenia. Infection occurred following lymphodepleting chemotherapy and afamit...
40423661
PMC12316539
melanoma signs symptoms warning
FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy.
full_text
symptom
Evaluating the use of new and advanced technologies in a population-based cancer registry Background: Cancer is typically a notifiable disease, with notifications captured in population-based cancer registries (PBCR) to inform public health cancer control. Despite the importance of PBCRs, a knowledge gap exists regard...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Objective: To examine the impact of electronic reporting, machine learning and automation on PBCR data quality and utility. Method: A mixed-methods, participatory, performance story evaluation was conducted in 2022 to examine data quality (completeness, coverage, timeliness and efficiency) and utility (real-time dashbo...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Results: A two-fold increase in cancer notifications was observed between 2012 and 2021 ( n = +171,841; 103% increase). Electronic data receipt increased by 63-percentage points between 2015 and 2021 (12% to 75%), and the number of services that provided electronic data also increased during this time. Timeliness of da...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Timeliness of data receipt improved between 2012 and 2021, with 87% ( n = 293,544) received on time in 2021. Manual requests, data extraction and processing times decreased from 4791 to 483 requests (2012–2021) and 921 to 63 days (2017–2021). Utility was enhanced, as supported by collaboration.
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Utility was enhanced, as supported by collaboration. Greater confidence in population-level quality improvement initiatives was reported, and an increase in research activity and functionality observed. Conclusion: Electronic reporting, machine learning and automation can improve data quality, utility and cancer contro...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Conclusion: Electronic reporting, machine learning and automation can improve data quality, utility and cancer control capability, with collaboration remaining essential. Implications for health information management practice: Innovative technologies and collaboration can improve PBCRs and strengthen health care, poli...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Introduction Population-based cancer registries (PBCRs) are the gold standard for population health cancer information ( North American Association of Central Cancer Registries, 2008 ). They enable the collection, analysis and reporting of cancer incidence, prevalence, mortality, survival and other cancer characteristi...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Central to public health programs, PBCRs help reduce cancer surveillance inaccuracies, inform health system and service planning ( Division of Cancer Control & Population Sciences, 2024 ), estimate future cancer burden and trends and strengthen research infrastructure ( Ahmed et al., 2024 ; Hernandez-Boussard et al., 2...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Reporting timeliness is a major priority for registry users ( Bray and Parkin, 2009 ), driven, in part, by the expanding utility and value of PBCRs. Novel and advanced digital data engineering technologies can improve PBCR health information management systems and the timeliness of registry reporting. Traditionally, re...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
Traditionally, registries have relied on manual data collection and analysis. However, these methods are costly, time-consuming, and prone to error; they deliver limited transparency and traceability and result in reporting time lags (or longer data latency periods) ( Offodile et al., 2021 ; Sutton et al., 2020 ; Tangk...
38970918
PMC12756513
melanoma signs symptoms warning
Innovative use of Australian cancer registry data for early detection of the effects of epidemics and other mass disruptions on cancer incidence.
full_text
general
End of preview.

LUMEN RAG Data

A chunked biomedical passage corpus with aligned precomputed embeddings and relevance judgments, built as the retrieval layer for LUMEN, the AI service behind the MediLink healthcare platform.

The corpus covers oncology literature drawn from PubMed and PMC, chunked for retrieval and paired with dense vectors from a biomedical bi-encoder. It ships with pooled relevance judgments for 30 queries, so retrieval quality can be measured on it directly. It's published so the retrieval stage of the system is reproducible without re-running ingestion or re-encoding 77K passages.

Files

File Size Contents
SpubMedBERT_chunks.json 60.2 MB 77,649 chunk records with metadata
embeddings_spubmedbert.npy 116 MB float16 array, shape (77649, 768)
qrels/lumen_qrels.tsv 9.6 kB Relevance judgments, TREC format
qrels/lumen_queries.jsonl 3.2 kB 30 queries with intent tags
qrels/lumen_pool.json 9.5 kB Pool composition and judging config

The corpus and embedding files are aligned row for row. Row i of the .npy is the embedding of chunk i in the JSON. Any filtering has to be applied to both together.

Schema

Field Type Description
text string Chunk text, 41–14,500 characters
pmid string PubMed identifier of the source article
pmcid string PMC identifier, empty when the article isn't in PMC
title string Source article title
keyword string Ingestion query that retrieved the article (13 classes)
source string Origin of the text, e.g. full_text (6 classes)
chunk_type string general or symptom

Topic distribution

The corpus was built by querying PubMed with 13 keyword strings. Five account for most of its mass:

Chunks Ingestion keyword
13,656 melanoma diagnosis clinical features
13,489 skin cancer types symptoms treatment
13,287 squamous cell carcinoma symptoms
12,852 multiple myeloma diagnosis signs
12,825 basal cell carcinoma signs symptoms
4,337 melanoma prevention UV protection
6,738 eight lower frequency keyword variants

Chunks are stored in ingestion order, so passages on the same topic occupy contiguous index ranges.

Embeddings

  • Model: pritamdeka/S-PubMedBert-MS-MARCO
  • Dimension: 768
  • Dtype: float16. Cast to float32 before matrix operations; float16 matmul is slow on CPU and loses precision at this scale
  • Normalization: vectors are stored unnormalized; L2 normalize before cosine similarity

Usage

import json
import numpy as np
from huggingface_hub import hf_hub_download

REPO = "mohamedkhaledmk7/LUMEN-rag-data"

chunks_path = hf_hub_download(REPO, "SpubMedBERT_chunks.json", repo_type="dataset")
embed_path  = hf_hub_download(REPO, "embeddings_spubmedbert.npy", repo_type="dataset")

with open(chunks_path) as f:
    chunks = json.load(f)

E = np.load(embed_path).astype("float32")
E /= np.linalg.norm(E, axis=1, keepdims=True) + 1e-12

assert E.shape[0] == len(chunks), "chunks and embeddings are misaligned"

Retrieval with the same encoder:

from sentence_transformers import SentenceTransformer

encoder = SentenceTransformer("pritamdeka/S-PubMedBert-MS-MARCO")
q = encoder.encode(["What is the ABCDE rule for melanoma detection?"],
                   normalize_embeddings=True)

scores = (q @ E.T)[0]
for i in np.argsort(-scores)[:5]:
    print(f"{scores[i]:.3f}  {chunks[i]['title'][:70]}")

Exact search over 77K vectors is a single dot product, no vector database required. The production system uses Weaviate for hybrid BM25 + dense retrieval, but that's a serving choice, not a requirement of the data.

Evaluation labels (qrels/)

Relevance judgments for 30 oncology queries, so nDCG, Recall@K, and MRR can be computed on this corpus the same way they're computed on labeled benchmarks like BEIR.

How they were built. Five retrieval configurations (dense only, MedCPT cross-encoder, and Cohere rerank-v3.5 / v4.0-fast / v4.0-pro) each contributed their top 10 per query over a shared top 100 candidate set. The union of all five, about 732 unique passages, roughly 25 per query after deduplication, was judged on a 0 to 3 relevance scale. Pooling from all five systems equally matters here: a pool drawn from a single reranker would score that reranker highly by construction.

Judging. Claude Haiku (claude-haiku-4-5-20251001), graded 0 to 3, following TREC assessment practice. The judge saw only a query and a passage, never which system retrieved it or at what rank. Pool order was shuffled per query too, so position carried no signal either.

Grade Meaning Share
3 Directly and substantially answers the query 33.1%
2 Partially answers the query 32.1%
1 On topic but doesn't answer the query 26.4%
0 Off topic 8.5%

Following BEIR convention, lumen_qrels.tsv only contains positive judgments. A (query, passage) pair that's absent from the file is non-relevant. The full judged pool, including grade-0 passages, is recorded in lumen_pool.json.

Reliability. A random 10% sample was re-judged across four independent runs: exact agreement 67 to 70%, within one grade agreement 98 to 100%. Disagreement is confined to adjacent grades. The judge separates relevant from irrelevant reliably, with some remaining uncertainty on the partial versus full answer boundary.

Loading:

from collections import defaultdict
from huggingface_hub import hf_hub_download

path = hf_hub_download(REPO, "qrels/lumen_qrels.tsv", repo_type="dataset")

qrels = defaultdict(dict)
with open(path) as f:
    next(f)                                   # header
    for line in f:
        qid, did, score = line.rstrip("\n").split("\t")
        qrels[qid][did] = int(score)          # did indexes into chunks / E

corpus-id is the integer row index into SpubMedBERT_chunks.json and the .npy, not a PMID.

Known properties of these labels

  • LLM generated, not human. Weaker evidence than a hand-annotated benchmark like NFCorpus. Report results on this dataset separately from human-labeled benchmarks rather than averaging the two together.
  • Pooling bias. A relevant passage that no pooled system ranked in its top 10 was never judged, and counts as non-relevant. Recall measured against these qrels only reflects what these five systems found. A sixth system evaluated later is mildly disadvantaged if it surfaces something all five missed. This is inherent to pooled evaluation, not specific to this dataset.
  • Queries are corpus derived. They were written against the corpus's known topic distribution, so nearly all of them are answerable. Absolute scores run higher than they would on real production traffic, where some questions have no good answer. System comparisons stay valid though, since every system faces the same conditions.
  • One query is a known hard case. LQ011 ("histological subtypes of cutaneous squamous cell carcinoma") draws half its pool from grade 0 passages spread across the full corpus index range. The corpus's squamous cell keyword is symptom oriented and carries little histopathology content. It's kept in deliberately, as a case where retrieval genuinely fails.

How it was used

In LUMEN, this corpus is served through Weaviate with intent aware hybrid retrieval (BM25 blended with dense, alpha = 0.60 by default and varied per query intent), followed by cross-encoder reranking with ncbi/MedCPT-Cross-Encoder and citation grounded generation.

Limitations

  • Scope. Oncology focused, driven by the 13 ingestion keywords. It's not a general biomedical corpus and will retrieve poorly outside its topics.
  • Keyword match drift. Ingestion matched on keyword strings, so some articles are topical false positives: oesophageal squamous cell carcinoma, hepatocellular carcinoma, CAR-T for rheumatoid arthritis. These act as genuine distractors in retrieval evaluation.
  • Chunk boundaries. Chunks are contiguous spans and some begin mid-sentence, carrying a trailing fragment of the previous chunk.
  • Not clinical guidance. Research literature, retrieved by keyword, not reviewed for clinical accuracy or currency. Not suitable for medical decision-making.

Licensing

Content is derived from PubMed abstracts and PMC articles. Terms vary per article: the PMC Open Access Subset carries per-article Creative Commons or similar licenses, while other PMC content is more restricted. Consult the terms for the underlying articles via the pmid / pmcid fields before redistributing or using commercially.

Citation

@misc{khaled2026lumen,
  title  = {LUMEN RAG Data: A Biomedical Passage Corpus with Aligned Embeddings
            and Pooled Relevance Judgments},
  author = {Mohamed Khaled},
  year   = {2026},
  url    = {https://huggingface.co/datasets/mohamedkhaledmk7/LUMEN-rag-data}
}
Downloads last month
85